You are here
Alemtuzumab for relapsing-remitting multiple sclerosis
Richard A Diaz, Sally Doss, Martyn J Burke, Elisabeth George, Amanda I Adler
The Lancet Neurology, Volume 13, Issue 9, September 2014, Pages 869–870
On May 28, 2014, the UK National Institute of Health and Care Excellence (NICE) published guidancerecommending alemtuzumab as an option, within its licence, for the treatment of relapsing-remitting multiple sclerosis (RRMS).
Alemtuzumab, a monoclonal antibody directed against lymphocytes, was appraised under the Single Technology Appraisal process. The appraisal'sremit was to assess the clinical and cost effectiveness of alemtuzumab, within its licensed indication, for the treatment of RRMS. Genzyme, who manufacture alemtuzumab under the brand name Lemtrada, submitted clinical evidence and a health economic model that was critiqued by an independent Evidence Review Group from the University of Southampton. A NICE Appraisal Committee met twice on Oct 22, 2013, and Feb 18, 2014, to consider the evidence, to hear from clinical specialists, patient experts, and Genzyme, and to develop the guidance.